Skip to main content

Exosome Diagnostics, Intezyne to Develop Exosomal RNA Assay for Novel CRP Inhibitor

NEW YORK (GenomeWeb) – Exosome Diagnostics said today that it has agreed to collaborate with Intezyne to design and validate an exosomal RNA assay for use in Intezyne's Phase 1/2 clinical trials of IT-139, a novel Cancer Resistance Pathway (CRP) inhibitor intended for the treatment of pancreatic, gastric, and other cancers in combination with existing anti-cancer therapies.

The assay will use Exosome Diagnostics' Exolution isolation kit and will be designed to stratify patients and monitor them longitudinally.

"As we delve further into the novel mechanism of action of IT-139, we needed a companion diagnostic assay that could reliably measure IT-139's impact on GRP78 levels," Suzanne Bakewell, VP of preclinical development at Intezyne, said in a statement.